US 12,391,663 B2
Isoindolinone compounds
Bernhard Fasching, Basel (CH); Thomas Ryckmans, Basel (CH); Alexander Flohr, Basel (CH); Andreas Ritzén, Basel (CH); Freya Harvey, Basel (CH); and Laura McAllister, Basel (CH)
Assigned to Monte Rosa Therapeutics AG, Basel (CH)
Filed by Monte Rosa Therapeutics AG, Basel (CH)
Filed on Oct. 27, 2023, as Appl. No. 18/496,504.
Application 18/496,504 is a continuation of application No. 18/349,634, filed on Jul. 10, 2023, granted, now 11,912,682.
Application 18/349,634 is a continuation of application No. PCT/EP2022/050699, filed on Jan. 13, 2022.
Claims priority of provisional application 63/281,049, filed on Nov. 18, 2021.
Prior Publication US 2024/0083869 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/04 (2006.01)
CPC C07D 401/04 (2013.01) 20 Claims
 
1. A compound or pharmaceutically acceptable salts or stereoisomers thereof of formula I:

OG Complex Work Unit Chemistry
wherein
X1 is linear or branched C1-6 alkyl, C3-8 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, CMeF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O-C1-6alkyl, —COOH, —C1-6alkylC(O) OH, —C1-6alkylC(O)O-C1-6alkyl, NH2, C1-4 alkoxy, C1-4 alkylhydroxy, —CH2F, —N(H) C(O)—O-C1-6 alkyl, and C(OH)(CF3);
or X1 together with the N atom of the carbamate forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched —C1-6 alkyl, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —C(O)O-C1-6alkyl, —COOH, —C1-6alkylC(O) OH, —C1-6alkylC(O)O-C1-6alkyl, NH2, C1-4 alkylhydroxy, and C1-4 alkoxy;
X2 is H, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, —C1-4 alkoxy, NH2, NMe2, halogen, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, and C1-4 alkylhydroxy;
L1 is a covalent bond, linear or branched C1-6 alkyl;
L2 is a covalent bond, linear or branched C1-6 alkyl; and
L3 is a covalent bond, linear or branched C1-6 alkyl, —O—, or —C1-4 alkoxy, wherein linear or branched C1-6 alkyl is unsubstituted or substituted with one or more of halogen.